Cardiomyopathy is a leading cause of heart failure in children, and there are currently no effective treatments. Could emerging therapies that successfully target the root cause of the condition in adults also work well in children? That was the question Dr....
In the realm of cardiac health, an exciting new study has cast light on the intricate details of our hearts, revealing significant differences between the left and right ventricles' fibroblasts. This research, conducted by a team of dedicated scientists from the...
For children diagnosed with complex heart conditions like hypertrophic cardiomyopathy (HCM), the diagnosis can be frightening for families and challenging for healthcare providers since the trajectory of the condition is often uncertain. As a leading cause of sudden...
An innovative cardiovascular start-up, HDAX Therapeutics, is the latest company to win $250,000 in funding following another year of the Ted Rogers Centre for Heart Research’s Entrepreneurship for Cardiovascular Health Opportunities (ECHO) program. The ECHO program...
Several members of the Ted Rogers Centre for Heart Research (TRCHR) participated in Vascular 2023, a five-day conference held in Montreal from October 25-29. The conference is a hallmark event organized by several Canadian specialist and research organizations,...
Researchers at the Ted Rogers Centre for Heart Research have developed an innovative approach to better understanding the complex signaling mechanisms underlying heart failure. A recent publication in the Proceedings of the National Academy of Sciences (PNAS) offers...
The planning committee for the 2021 Ted Rogers Centre Heart Failure Symposium is pleased to welcome all clinicians, investigators, trainees and interested parties to join this year’s virtual meeting on Dec. 10-11, 2021. This meeting, which blends clinical innovations with the latest scientific advances, has grown to become Canada’s largest conference on heart failure.
On Friday, December 10th, our research-focused symposium examines congenital heart disease, and how we can take animal models and regenerative medicine approaches to answer the clinical challenges that remain. It also highlights commercialization success stories, and sees how innovators developed an idea and translated it to impact. And it will shine a light on unique new scientific approaches in the emerging field of cardiotoxicity.
On Saturday, December 11th, we will reprise a very popular program for primary care practitioners who manage patients with (or at risk of) heart failure, as well as other front-line health-care professionals. Experts will address a range of topics that include emerging therapies, new standards of care, nurse-led initiatives, wearable technology, comorbidities and caring for specialized populations and complex cases. This program will be submitted for accreditation.